Mohammad Reze Aghasadeghi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8227729/publications.pdf

Version: 2024-02-01

83 papers 1,368 citations

331259 21 h-index 32 g-index

84 all docs 84 docs citations

84 times ranked 2266 citing authors

#	Article	IF	CITATIONS
1	Polymeric nanoparticles. Human Vaccines and Immunotherapeutics, 2014, 10, 321-332.	1.4	219
2	HIV-1 Vpr Protein Enhances Proteasomal Degradation of MCM10 DNA Replication Factor through the Cul4-DDB1[VprBP] E3 Ubiquitin Ligase to Induce G2/M Cell Cycle Arrest. Journal of Biological Chemistry, 2015, 290, 17380-17389.	1.6	56
3	Synthesis, biological evaluation, and molecular modeling studies of new 1,3,4-oxadiazole- and 1,3,4-thiadiazole-substituted 4-oxo-4H-pyrido[1,2-a]pyrimidines as anti-HIV-1 agents. Medicinal Chemistry Research, 2013, 22, 2467-2475.	1.1	49
4	Smart bomb <scp>AS</scp> 1411 aptamerâ€functionalized/ <scp>PAMAM</scp> dendrimer nanocarriers for targeted drug delivery in the treatment of gastric cancer. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 41-51.	0.9	48
5	MPG-based nanoparticle: An efficient delivery system for enhancing the potency of DNA vaccine expressing HPV16E7. Vaccine, 2015, 33, 3164-3170.	1.7	47
6	The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients. Virology Journal, 2021, 18, 221.	1.4	41
7	Prevalence of Transmitted HIV Drug Resistance in Iran between 2010 and 2011. PLoS ONE, 2013, 8, e61864.	1.1	39
8	HIV-1 Vpr Protein Induces Proteasomal Degradation of Chromatin-associated Class I HDACs to Overcome Latent Infection of Macrophages. Journal of Biological Chemistry, 2016, 291, 2696-2711.	1.6	35
9	HIV-1 Vpr reactivates latent HIV-1 provirus by inducing depletion of class I HDACs on chromatin. Scientific Reports, 2016, 6, 31924.	1.6	32
10	Synthesis and evaluation of antiviral activities of novel sonochemical silver nanorods against HIV and HSV viruses. Asian Pacific Journal of Tropical Disease, 2016, 6, 854-858.	0.5	30
11	Serum Bactericidal Antibody Response 1 Year after Meningococcal Polysaccharide Vaccination of Patients with Common Variable Immunodeficiency. Vaccine Journal, 2010, 17, 524-528.	3.2	27
12	Application of Outer Membrane Vesicle of Neisseria meningitidis Serogroup B as a New Adjuvant to Induce Strongly Th1-Oriented Responses Against HIV-1. Current HIV Research, 2011, 9, 630-635.	0.2	27
13	Nanosilver based anionic linear globular dendrimer with a special significant antiretroviral activity. Journal of Materials Science: Materials in Medicine, 2015, 26, 179.	1.7	26
14	Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses. Immunology Letters, 2015, 168, 366-373.	1.1	26
15	Vulnerability of Homeless People in Tehran, Iran, to HIV, Tuberculosis and Viral Hepatitis. PLoS ONE, 2014, 9, e98742.	1.1	26
16	Tumor cell-based vaccine: an effective strategy for eradication of cancer cells. Immunotherapy, 2022, 14, 639-654.	1.0	25
17	Design, Synthesis and Docking Studies of New 4-hydroxyquinoline-3-carbohydrazide Derivatives as Anti-HIV-1 Agents. Drug Research, 2013, 63, 192-197.	0.7	24
18	Comparison of Three Different Methods for Detection of IL28 rs12979860 Polymorphisms as a Predictor of Treatment Outcome in Patients with Hepatitis C Virus. Osong Public Health and Research Perspectives, 2016, 7, 83-89.	0.7	23

#	Article	IF	CITATIONS
19	Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice. Virus Genes, 2010, 40, 44-52.	0.7	22
20	Novel quinolone-3-carboxylic acid derivatives as anti-HIV-1 agents: design, synthesis, and biological activities. Medicinal Chemistry Research, 2016, 25, 1861-1876.	1.1	22
21	Novel chlorambucil-conjugated anionic linear-globular PEG-based second-generation dendrimer: in vitro/in vivo improved anticancer activity. OncoTargets and Therapy, 2016, Volume 9, 5531-5543.	1.0	21
22	Transmitted Drug Resistance Mutations in Antiretroviral-NaÃ-ve Injection Drug Users with Chronic HIV-1 Infection in Iran. PLoS ONE, 2015, 10, e0126955.	1.1	21
23	High Resolution Melting Curve Assay for Detecting rs12979860 IL28B Polymorphisms Involved in Response of Iranian Patients to Chronic Hepatitis C Treatment. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1873-1880.	0.5	21
24	Conjugated linoleic acidâ€producing enzymes: A bioinformatics study. European Journal of Lipid Science and Technology, 2010, 112, 1088-1100.	1.0	19
25	Prevalence of Occult Hepatitis B Virus in Plasma and Peripheral Blood Mononuclear Cell Compartments of Patients WithChronic Hepatitis C Infection in Tehran-Iran. Hepatitis Monthly, 2013, 13, e10134.	0.1	19
26	Induction of IFN- \hat{l}^3 cytokine response against hepatitis B surface antigen using melittin. Gastroenterology and Hepatology From Bed To Bench, 2014, 7, 108-17.	0.6	19
27	Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19. Molecular Biotechnology, 2021, 63, 389-409.	1.3	17
28	Antiretroviral drug resistance mutations in $na\tilde{A}$ ve and experienced patients in Shiraz, Iran, 2014. Archives of Virology, 2016, 161, 2503-2509.	0.9	15
29	Frequency and Genotype of Hepatitis D Virus Infection in Patients Infected with HIV and Those Undergoing Hemodialysis. Hepatitis Monthly, 2013, 13, e7481.	0.1	14
30	Conjugated anionic PEG-citrate G2 dendrimer with multi-epitopic HIV-1 vaccine candidate enhance the cellular immune responses in mice. Artificial Cells, Nanomedicine and Biotechnology, 2017, 45, 1762-1768.	1.9	14
31	IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C. Archives of Virology, 2017, 162, 181-189.	0.9	14
32	Application of SCR Priming VLP Boosting as a Novel Vaccination Strategy Against HIV-1. Current HIV Research, 2011, 9, 140-147.	0.2	13
33	Occult hepatitis B virus infection and S gene escape mutants in HIV-infected patients after hepatitis B virus vaccination. International Journal of STD and AIDS, 2016, 27, 967-972.	0.5	13
34	Isolated Anti-HBc and Occult HBV Infection in Dialysis Patients. Nephro-Urology Monthly, 2014, 7, e22674.	0.0	12
35	QSAR and docking studies of some 1,2,3,4-tetrahydropyrimidines: evaluation of gp41 as possible target for anti-HIV-1 activity. Medicinal Chemistry Research, 2015, 24, 1707-1724.	1.1	12
36	The in vitro anti-viral potential of Setarud (IMODâ,,¢), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials. Indian Journal of Pharmacology, 2012, 44, 448.	0.4	11

#	Article	IF	Citations
37	First detection of human hepegivirus-1 (HHpgV-1) in Iranian patients with hemophilia. Scientific Reports, 2018, 8, 5036.	1.6	11
38	Comparative study of μ â€stat methanol feeding control in fedâ€batch fermentation of Pichia pastoris producing HBsAg: an openâ€loop control versus recurrent artificial neural networkâ€based feedback control. Journal of Chemical Technology and Biotechnology, 2019, 94, 3924-3931.	1.6	11
39	Application of recurrent neural network for online prediction of cell density of recombinant <i>Pichia pastoris</i> producing HBsAg. Preparative Biochemistry and Biotechnology, 2019, 49, 352-359.	1.0	11
40	Construction and Immunogenicity Analysis of Hepatitis C Virus (HCV) Truncated Non-Structural Protein 3 (NS3) Plasmid Vaccine. Jundishapur Journal of Microbiology, 2016, 9, e33909.	0.2	11
41	Reduced efficacy of multiple doses of CpG-matured dendritic cell tumor vaccine in an experimental model. Cellular Immunology, 2011, 271, 360-364.	1.4	10
42	Preparation and Evaluation of a New Lipopolysaccharide-based Conjugate as a Vaccine Candidate for Brucellosis. Osong Public Health and Research Perspectives, 2015, 6, 9-13.	0.7	10
43	Prevalence of Merkel Cell Polyomavirus in Tehran: An Age-Specific Serological Study. Iranian Red Crescent Medical Journal, 2016, 18, e26097.	0.5	10
44	Clustered epitopes within a new poly-epitopic HIV-1 DNA vaccine shows immunogenicity in BALB/c mice. Molecular Biology Reports, 2014, 41, 5207-5214.	1.0	9
45	Design, synthesis and anti-HIV-1 evaluation of a series of 5-hydroxypyridine-4-one derivatives as possible integrase inhibitors. Medicinal Chemistry Research, 2015, 24, 4113-4127.	1.1	9
46	Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses. Pathogens and Global Health, 2016, 110, 39-47.	1.0	9
47	Venom Components of Iranian Scorpion Hemiscorpius lepturus Inhibit the Growth and Replication of Human Immunodeficiency Virus 1 (HIV-1). Iranian Biomedical Journal, 2016, 20, 259-65.	0.4	9
48	Outer membrane vesicle ofNeisseria meningitidis serogroup B as an adjuvant to induce specific antibody response against the lipopolysaccharide ofBrucella abortus S99. Annals of Microbiology, 2009, 59, 145-149.	1.1	8
49	Immunization of Mice by BCG Formulated HCV Core Protein Elicited Higher Th1-Oriented Responses Compared to Pluronic-F127 Copolymer. Hepatitis Monthly, 2013, 13, e14178.	0.1	8
50	Prevalence and Risk Factors of Hepatitis B Virus Genotype D Amongst Inmates in Alborz Province, Iran: A Cross-Sectional Survey. Jundishapur Journal of Microbiology, 2013, 6, .	0.2	7
51	Cellular uptake, imaging and pathotoxicological studies of a novel Gd[<scp>iii</scp>]–DO3A-butrol nano-formulation. RSC Advances, 2014, 4, 45984-45994.	1.7	7
52	Expression and Purification of the Uropathogenic Escherichia coli PapG Protein and its Surface Absorption on Lactobacillus reuteri: Implications for Surface Display System Vaccines. Jundishapur Journal of Microbiology, 2015, 8, e25595.	0.2	7
53	From in-silico immunogenicity verification to in vitro expression of recombinant Core-NS3 fusion protein of HCV. Bratislava Medical Journal, 2017, 118, 189-195.	0.4	7
54	Lamivudineâ€conjugated and efavirenzâ€loaded G2 dendrimers: Novel antiâ€retroviral nano drug delivery systems. IET Nanobiotechnology, 2021, 15, 627-637.	1.9	7

#	Article	IF	Citations
55	Impact of TGF- $\hat{1}^21$ Gene Polymorphism (rs 1800469) on Treatment Response to Pegylated Interferon/Ribavirin in Iranian Patients with Hepatitis C. Clinical Laboratory, 2016, 62, 609-14.	0.2	7
56	Detection of Hepatitis B Virus Variants in HBV Monoinfected and HBV/HIV Coinfected Iranian Patients Under Lamivudine Treatment. Current HIV Research, 2011, 9, 263-269.	0.2	6
57	Neutralizing Antibody Response after Intramuscular Purified Vero Cell Rabies Vaccination (PVRV) in Iranian Patients with Specific Medical Conditions. PLoS ONE, 2015, 10, e0139171.	1.1	6
58	Docking studies of some 5-hydroxypyridine-4-one derivatives: evaluation of integrase and ribonuclease H domain of reverse transcriptase as possible targets for anti-HIV-1 activity. Medicinal Chemistry Research, 2015, 24, 2195-2212.	1.1	6
59	Recombinant C-terminal 311 amino acids of HapS adhesin as a vaccine candidate for nontypeable Haemophilus influenzae: A study on immunoreactivity in Balb/C mouse. Microbial Pathogenesis, 2016, 98, 106-111.	1.3	6
60	No evidence of occult HBV infection in population born after mass vaccination. Wiener Medizinische Wochenschrift, 2020, 170, 218-223.	0.5	6
61	Impact of null genotypes of GSTT1 and GSTM1 with uterine leiomyoma risk in Iranian population. Journal of Obstetrics and Gynaecology Research, 2016, 42, 434-439.	0.6	5
62	Cloning, Expression and Purification of a Novel Multi-epitopic HIV-1 Vaccine Candidate: A Preliminary Study on Immunoreactivity. Vaccine Research, 2014, 1, 10-15.	0.3	5
63	Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C. Iranian Red Crescent Medical Journal, 2016, 18, e28566.	0.5	5
64	Measurement of opsonophagocytic activity of antibodies specific toNeisseria meningitidis serogroup A capsular polysaccharide-serogroup B outer membrane vesicle conjugate in animal model. Annals of Microbiology, 2009, 59, 801-806.	1.1	4
65	Magnetic Resonance Contrast Media Sensing In Vivo Molecular Imaging Agents: An Overview. Current Radiopharmaceuticals, 2011, 4, 31-43.	0.3	4
66	Immune responses regulation following antitumor dendritic cell-based prophylactic, concurrent, and therapeutic vaccination. Medical Oncology, 2011, 28, 660-666.	1.2	4
67	Biodistribution properties of cleistanthin A and cleistanthin B using magnetic resonance imaging in a normal and tumoric animal model. Pharmacognosy Magazine, 2012, 8, 129.	0.3	4
68	Biological and Immunological Evaluation of <italic>Neisseria meningitidis</italic> Serogroup A Outer Membrane Vesicle as Vaccine Candidates. Jundishapur Journal of Microbiology, 2013, 6, .	0.2	4
69	Low prevalence of hepatitis B vaccine escape mutants among individuals born after the initiation of a nationwide vaccination program in Iran. Archives of Virology, 2016, 161, 3405-3411.	0.9	4
70	Functional recombinant extra membrane loop of human CD20, an alternative of the full length CD20 antigen. Iranian Biomedical Journal, 2012, 16, 121-6.	0.4	4
71	Correlation Study Between IL-28B Gene Polymorphism (rs8099917SNP) and Sustained Virological Response in Iranian Patients with Chronic Hepatitis C. Clinical Laboratory, 2016, 62, 417-23.	0.2	4
72	Immunological evaluation of predicted linear Bâ€eell epitopes of human CD20 antigen. Biotechnology and Applied Biochemistry, 2012, 59, 186-192.	1.4	3

#	Article	IF	CITATIONS
73	Inducing Humoral Immune Responses Against Regulatory T Cells by Foxp3-Fc(IgG) Fusion Protein. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2015, 34, 381-385.	0.8	3
74	Comparison of antiretroviral drug resistance among treatment-naive and treated HIV-infected individuals in Shiraz, Iran. Archives of Virology, 2018, 163, 99-104.	0.9	3
75	Nanosized Tamoxifen-Porphyrin-Glucose [TPG] Conjugate: Novel Selective Anti-breast-cancer Agent, Synthesis and In Vitro Evaluations. Medicinal Chemistry, 2013, 9, 526-538.	0.7	3
76	Evaluation of Truncated HCV-NS3 Protein for Potential Applications in Immunization and Diagnosis. Clinical Laboratory, 2016, 62, 1271-1278.	0.2	3
77	Presence of plus-strand HCV RNA in serum and PBMCs as an indicator for relapse and resistance to IFN therapy in patients infected by HCV. Future Virology, 2012, 7, 323-330.	0.9	2
78	Introducing a frameshift mutation to the Pol sequence of HIV-1 provirus and evaluation of the immunogenic characteristics of the mutated virions (RINNL4-3). Molecular Biology, 2012, 46, 467-472.	0.4	2
79	Importance of evaluating occult HBV risk factors in aÂlow endemic area for HBV infection. Wiener Medizinische Wochenschrift, 2021, 171, 16-17.	0.5	1
80	Genotypic and Phenotypic Comparison of Enteroaggregative Escherichia coli Isolates from HIV-Positive and Non-HIV Diarrheal Samples. Current HIV Research, 2014, 11, 635-641.	0.2	1
81	Design, Construction and Evaluation of $1a$ /JFH1 HCV Chimera by Replacing the Intergenotypic Variable Region. Hepatitis Monthly, 2016, 16, e38261.	0.1	1
82	Novel Molecular Anti- Colorectalcancer Conjugate: Chlorambucil-Adipic Acid Dihydrizide-Glutamine. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1449-1459.	0.9	1
83	Expression of HCV Alternative Reading Frame Protein (Core+ $1/F$) in Baculovirus Expression System and its Evaluation for Assessment of Specific Anti-core+ 1 Antibody in Iranian HCV Infected Patients. Clinical Laboratory, 2016, 62, 1919-1926.	0.2	1